INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $18,400,000 | -37.6% | 24,475,000 | -32.7% | 0.02% | -47.5% |
Q1 2020 | $29,468,000 | -63.3% | 36,360,000 | -54.3% | 0.04% | -45.2% |
Q4 2019 | $80,207,000 | +14.8% | 79,610,000 | -0.7% | 0.07% | +5.8% |
Q3 2019 | $69,869,000 | -1.9% | 80,210,000 | 0.0% | 0.07% | +4.5% |
Q2 2019 | $71,198,000 | -26.0% | 80,210,000 | -17.3% | 0.07% | -30.5% |
Q1 2019 | $96,216,000 | +17.3% | 96,985,000 | +5.6% | 0.10% | +5.6% |
Q4 2018 | $82,043,000 | -13.6% | 91,840,000 | -3.1% | 0.09% | +4.7% |
Q3 2018 | $94,974,000 | +148.1% | 94,760,000 | +118.4% | 0.09% | +132.4% |
Q2 2018 | $38,287,000 | +11.0% | 43,385,000 | 0.0% | 0.04% | +12.1% |
Q1 2018 | $34,491,000 | -5.4% | 43,385,000 | -3.3% | 0.03% | +13.8% |
Q4 2017 | $36,469,000 | +0.9% | 44,885,000 | -3.2% | 0.03% | -6.5% |
Q3 2017 | $36,157,000 | +823.3% | 46,385,000 | +1059.6% | 0.03% | +675.0% |
Q2 2017 | $3,916,000 | +5.0% | 4,000,000 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $3,728,000 | +3.4% | 4,000,000 | 0.0% | 0.00% | +33.3% |
Q4 2016 | $3,606,000 | -87.0% | 4,000,000 | -83.8% | 0.00% | -88.9% |
Q3 2016 | $27,754,000 | – | 24,765,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |